Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Diagnostisk noggrannhet av en panel av bakteriella genmarkörer (M3) för kolorektal avancerad neoplasi (M3-PRO)

21 september 2026 uppdaterad av: Louis Ho Shing Lau, Chinese University of Hong Kong

En prospektiv tvärsnittsstudie för att bedöma den diagnostiska noggrannheten hos en panel av bakteriella genmarkörer (M3) för kolorektal avancerad neoplasi

The investigators aim to evaluate and compare the diagnostic accuracy of FIT and the novel panel of bacterial gene markers (Fn, m3, Ch and Bc) collectively named as M3, in detecting colorectal advanced neoplasia.

Studieöversikt

Status

Aktiv, inte rekryterande

Detaljerad beskrivning

Colorectal cancer (CRC) is the one of the most common cancers in Hong Kong with more than 5,500 new cases annually. There is prevailing evidence of increasing trend of young onset CRC globally. Early detection and resection of pre-malignant colorectal neoplasia has shown to reduce CRC-related mortality.

Non-invasive stool tests including guaiac-based faecal occult blood tests (gFOBT) and faecal immunochemical tests (FIT) are the cornerstones of population-based CRC screening programmes. The major limitation of this widely used strategy is its unsatisfactory sensitivities for CRC (79%) and advanced adenomas (AA; 40%). The sensitivity for non-advanced adenomas is even lower than 10%. A large proportion of advanced and non-advanced adenomas will be missed by FIT alone. Therefore, identification of alternative non-invasive test with better sensitivity to detect colorectal neoplasia is warranted.

Multitarget stool DNA test and faecal microbial DNA markers appear to be promising options for CRC screening. Several bacterial gene markers have been identified by metagenome sequencing and reported to be associated with CRC, including Fusobacterium nucleatum (Fn), Clostridium hathewayi (Ch) and Bacteroides clarus (Bc). However, these molecular markers had low accuracy in distinguishing adenomas from normal tissue. Recently, a new Lachnoclostridium gene marker (labelled as 'm3') has been shown to have high diagnostic yield for the detection of colorectal adenomas. In a case-control study of 1012 subjects, a linear increasing trend of m3 level was observed from fecal samples of healthy subjects to those with adenomas and cancers. The overall sensitivity of m3 was significantly higher than FIT in detecting all adenomas (48% vs 9.3%), AA (50.8% vs 16.1%) and non-advanced adenomas (44.2% vs 0%). The diagnostic accuracy of m3 could be further enhanced by combining with a panel of fecal microbial markers composing of Fusobacterium nucleatum (Fn), Bacteroides clarus (Bc), Clostridium hathewayi (Ch) for CRC (82.3%) and adenomas (64.2%). We hypothesized that the combination of these 4 bacterial gene markers (known as M3) is more sensitive than FIT in detecting colorectal advanced neoplasia.

Studietyp

Observationell

Inskrivning (Beräknad)

2500

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

      • Hong Kong, Hong Kong
        • Prince of Wales Hospital

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Ja

Kön som är behöriga för studier

Allt

Testmetod

Icke-sannolikhetsprov

Studera befolkning

Subjects with average risk of colorectal neoplsia requring screening/surveillance colonoscopy

Beskrivning

Inclusion Criteria:

  1. They require elective colonoscopy for colorectal cancer screening or polyp surveillance, or investigation of symptoms (e.g. anemia, change of bowel habit, abdominal pain);
  2. Aged ≥18 years old;
  3. Written informed consent obtained.

Exclusion Criteria:

  1. Contraindications to colonoscopy (e.g. perforation, intestinal obstruction, unstable cardiopulmonary status);
  2. Contraindication to polyp resection (e.g. active gastrointestinal bleeding, uninterrupted anticoagulation or dual antiplatelets);
  3. Known colorectal cancer or adenoma for staged procedure;
  4. Previous colonic resection;
  5. Personal history of colorectal cancer;
  6. Personal history of polyposis syndrome;
  7. Personal history of inflammatory bowel disease;
  8. Known pregnancy or lactation;
  9. Advanced comorbid conditions (defined as American Society of Anesthesiologists grade 4 or above);

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Observationsmodeller: CASE_ONLY
  • Tidsperspektiv: CROSS_SECTIONAL

Kohorter och interventioner

Grupp / Kohort
Intervention / Behandling
Colorectal neoplasia screening/surveillance cohort

Subjects with average risk of colorectal neoplasias requiring screening/surveillance colonoscopy

A kind of stool test

Andra namn:
  • Bakteriell genmarkörtest

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Sensitivity of bacterial gene markers panel (M3)
Tidsram: 1 month

The proportion of subjects with true positive results of M3 among those with one of more advanced neoplasia detected in the index colonoscopy.

1 month
Sensitivity of FIT/FOBT
Tidsram: 1 month

The proportion of subjects with true positive results of FIT among those with one of more advanced neoplasia detected in the index colonoscopy.

1 month

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Sensitivity of M3 for early-stage (stage 1) or invasive (stage 2-4) colorectal cancers
Tidsram: 1 month

The proportion of subjects with true positive results of M3 among those with early-stage (stage 1) or invasive (stage 2-4) colorectal cancers detected in the index colonoscopy.

1 month
Sensitivity of FIT/FOBT for early-stage (stage 1) or invasive (stage 2-4) colorectal cancers
Tidsram: 1 month

The proportion of subjects with true positive results of FIT among those with early-stage (stage 1) or invasive (stage 2-4) colorectal cancers detected in the index colonoscopy.

1 month
Sensitivity of FIT/FOBT for advanced adenomas
Tidsram: 1 month

The proportion of subjects with true positive results of FIT among those with one or more advanced adenomas detected in the index colonoscopy.

1 month
Sensitivity of M3 for advanced adenomas
Tidsram: 1 month

The proportion of subjects with true positive results of M3 among those with one or more advanced adenomas detected in the index colonoscopy.

1 month
Sensitivity of FIT/FOBT for all adenomas
Tidsram: 1 month

The proportion of subjects with true positive results of FIT among those with all advanced adenomas detected in the index colonoscopy.

1 month
Sensitivity of M3 for all adenomas
Tidsram: 1 month

The proportion of subjects with true positive results of M3 among those with all advanced adenomas detected in the index colonoscopy.

1 month
Sensitivity of FIT/FOBT for sessile serrated lesions (SSL)
Tidsram: 1 month

The proportion of subjects with true positive results of FIT among those with SSLs detected in the index colonoscopy.

1 month
Sensitivity of M3 for sessile serrated lesions (SSL)
Tidsram: 1 month

The proportion of subjects with true positive results of M3 among those with SSLs detected in the index colonoscopy.

1 month
Specificity
Tidsram: 1 month

The proportion of true negative results of M3/FOBT/FIT among those with no adenoma detected in colonoscopy

1 month
Positive predictive value (PPV)
Tidsram: 1 month

The ratio of subjects truly diagnosed as positive to all those who had positive test results

1 month
Negative predictive value (NPV)
Tidsram: 1 month

The ratio of subjects truly diagnosed as negative to all those who had negative test results

1 month
Overall diagnostic accuracy
Tidsram: 1 month

The proportion of correctly classified subjects among all subjects

1 month
Microbiota changes in subjects with adenomas or normal findings after polypectomy
Tidsram: 1 month

Microbiota change measured by qPCR or metagenomic sequencing

1 month

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

29 juni 2022

Primärt slutförande (Faktisk)

7 maj 2025

Avslutad studie (Beräknad)

31 december 2030

Studieregistreringsdatum

Först inskickad

1 juni 2022

Först inskickad som uppfyllde QC-kriterierna

1 juni 2022

Första postat (Faktisk)

6 juni 2022

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

24 september 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

21 september 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera